May 23, 2018 / 1:27 PM / 3 months ago

BRIEF-Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint

May 23 (Reuters) - Esperion Therapeutics Inc:

* ESPERION ANNOUNCES THIRD PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID MEETS PRIMARY ENDPOINT

* ESPERION - STUDY 3 ACHIEVES ADDITIONAL 26% LDL-C LOWERING ON BACKGROUND OF MAXIMALLY TOLERATED LDL-C LOWERING THERAPY IN PATIENTS CONSIDERED STATIN INTOLERANT

* ESPERION THERAPEUTICS INC - CUMULATIVE PHASE 2 / PHASE 3 DEMONSTRATES BROAD EFFICACY AS WELL AS SAFETY AND TOLERABILITY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below